Advertisement

Topics

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

2018-10-12 10:43:18 | BioPortfolio

Published on BioPortfolio: 2018-10-12T10:43:18-0400

Clinical Trials [2393 Associated Clinical Trials listed on BioPortfolio]

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

The purpose of this study is to assess the efficacy and safety of Ibrutinib in predominantly Asian patients with relapsed or refractory marginal zone lymphoma.

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qualify for such. Depending on t...

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

This phase II trial studies how well carfilzomib with or without rituximab work in treating patients with Waldenstrom macroglobulinemia or marginal zone lymphoma that is previously untreat...

Obinutuzumab in Marginal Zone Lymphoma

For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy are widely used for those patients who fail local therapy or do not qualify for such. Depending on ...

Gemcitabine for Marginal Zone Lymphoma

Marginal zone lymphoma, one of the indolent lymphoma, is believed to be incurable with chemotherapy. Thus the investigators need a novel agent for marginal zone lymphoma. Gemcitabine has b...

PubMed Articles [2307 Associated PubMed Articles listed on BioPortfolio]

Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.

Pediatric and adult patients with recurrent/refractory Burkitt lymphoma (BL) continue to have poor outcomes, emphasizing the need for newer therapeutic agents. Bruton's tyrosine kinase (BTK) is activa...

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small l...

Central nervous system involvement in primary bone marrow or splenic marginal zone lymphoma: Report of two cases and review of the literature.

We present two cases of splenic/primary bone marrow marginal zone lymphoma with secondary leptomeningeal CNS involvement, successfully treated with both systemic and intrathecal immunotherapy and we r...

Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution.

Given the paucity of data on higher-grade transformation (HGT) to aggressive lymphoma in patients with marginal zone lymphoma (MZL), we report on a large cohort of patients, identify risk factors, and...

Dural based marginal zone lymphoma in a patient with sarcoidosis: a case report.

Primary dural based lymphoma is a rare disease entity. It has beenhypothesized that patients with sarcoidosis are at increased risk of developing lymphoma, an association known as "sarcoidosis-lymphom...

Medical and Biotech [MESH] Definitions

Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.

A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.

The flowing of blood from the marginal gingival area, particularly the sulcus, seen in such conditions as GINGIVITIS, marginal PERIODONTITIS, injury, and ASCORBIC ACID DEFICIENCY.

The degree of approximation or fit of filling material or dental prosthetic to the tooth surface. A close marginal adaptation and seal at the interface is important for successful dental restorations.

The B-cell leukemia/lymphoma-1 genes, associated with various neoplasms when overexpressed. Overexpression results from the t(11;14) translocation, which is characteristic of mantle zone-derived B-cell lymphomas. The human c-bcl-1 gene is located at 11q13 on the long arm of chromosome 11.

More From BioPortfolio on "MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial